This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): Omnitarg, pertuzumab, rhuMab 2C4, R1273, RG1273, RO4368451
Description: Like Herceptin, Omnitarg is an anti-HER2 monoclonal antibody. While Herceptin use is currently limited to tumors that overexpress HER2, Genentech is developing Omnitarg for tumors in which HER2 is expressed at normal levels. According to Genentech, preclinical evidence suggests that Omnitarg blocks the growth of lung, breast, prostate, and colon cancer cell lines in vitro. Omnitarg may also sensitize tumor cells to chemotherapy.
Genentech & Roche
Genentech has a July 1998 licensing and marketing agreement relating to anti-HER2 antibodies (Herceptin and Omnitarg) with Hoffmann-La Roche, providing them with exclusive marketing rights outside of the U.S. Under the agreement, Hoffmann-La Roche funds one-half the global development costs incurred in connection with developing new indications under the agreement. Either Genentech or Hoffmann-La Roche has the right to opt-out of developing an additional indication for a product and would not share the costs or benefits of the additional indication, but could opt-back-in before approval of the indication by paying twice what would have been owed for development of the indication if no opt-out had occurred. Hoffmann-La Roche has also agreed to make royalty payments of 20% on aggregate net product sales outside the U.S. up to $500.0 million in each calendar year and 22.5% on such sales inexcess of $500.0 million in each calendar year.
In March 2009,...See full deal structure in Biomedtracker
Partners: Chugai Pharmaceutical Co., Ltd. PDL BioPharma, Inc.
Additional information available to subscribers only: